玻璃体腔注射甲氨蝶呤治疗复发性孔源性视网膜脱离中增生性玻璃体视网膜病变的真实世界疗效
回顾性队列纳入41只复发性孔源性视网膜脱离伴C1至D级增生性玻璃体视网膜病变的眼,均行平坦部玻璃体切除术并系列甲氨蝶呤注射,分改良Gain Understanding Against Retinal Detachment方案组27眼与未采用该方案组14眼。末次随访时视网膜复位率组1为77.8%、组2为71.4%,无统计学差异;logMAR改善组1为0.50、组2为0.44,中位随访12.1个月,术后并发症无差异。
要点
- 改良Gain Understanding Against Retinal Detachment方案组与未采用组视网膜复位率分别为77.8%与71.4%,无统计学差异。
- 两组logMAR视力改善分别为0.50与0.44,术后并发症无差异。
- 总体复位率超过既往报告的复发性孔源性视网膜脱离伴增生性玻璃体视网膜病变的复位率。
核心结论
- 两种甲氨蝶呤方案在视网膜复位或视力结局方面无差异。
- 总体复位率超过既往报告的复发性孔源性视网膜脱离伴增生性玻璃体视网膜病变的复位率。
- 需要进一步研究以优化注射方案以获得更好的临床结局。
研究设计与样本
- 回顾性队列研究,纳入41只既往孔源性视网膜脱离修复失败、表现为复发性孔源性视网膜脱离伴C1至D级增生性玻璃体视网膜病变的眼。
- 所有眼接受平坦部玻璃体切除术并系列甲氨蝶呤注射,分为组1(采用改良Gain Understanding Against Retinal Detachment方案,n=27)和组2(未采用该方案,n=14)。
主要发现
- 末次随访时无需额外手术即实现视网膜复位:组1为21眼(77.8%),组2为10眼(71.4%),无统计学差异。
- logMAR改善:组1为0.50,组2为0.44。
- 自手术起中位随访12.1个月,术后并发症无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以优化注射方案以获得更好的临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of serial intravitreal methotrexate injections as an adjunct to surgical repair in the management of recurrent rhegmatogenous retinal detachment because of proliferative vitreoretinopathy. METHODS: A retrospective cohort study was conducted involving 41 eyes with a history of failed rhegmatogenous retinal detachment repair presenting with recurrent rhegmatogenous retinal detachment and grade C1 to D proliferative vitreoretinopathy, treated with pars plana vitrectomy and serial methotrexate injections were included, separated into group 1 (with modified Gain Understanding Against Retinal Detachment protocol, n = 27) and group 2 (without modified Gain Understanding Against Retinal Detachment protocol, n = 14). The primary outcome was retinal reattachment rate, and secondary outcomes were changes in visual acuity and postoperative complications. RESULTS: Retinal reattachment was achieved without additional surgery in 21 (77.8%) eyes in group 1 and 10 (71.4%) in group 2 at final follow-up, with no statistical significance. Improvement in logarithm of the minimal angle of resolution was 0.50 in group 1 and 0.44 in group 2, with a median follow-up of 12.1 months from surgery and no differences in postoperative complications. CONCLUSION: There were no differences in retinal reattachment or visual acuity outcomes between both methotrexate regimens. The overall reattachment rate exceeded previously reported rates for recurrent rhegmatogenous retinal detachment with proliferative vitreoretinopathy. Further research is needed to optimize the injection protocol for better clinical outcomes.
引用
- Yun JS, Fortes BH, Yamamoto MH, et al. REAL-WORLD EFFICACY OF INTRAVITREAL METHOTREXATE FOR MANAGING PROLIFERATIVE VITREORETINOPATHY IN RECURRENT RHEGMATOGENOUS RETINAL DETACHMENT. Retina. 2025. PMID: 40632995. doi:10.1097/IAE.0000000000004602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。